Scavenger Receptor B1 is a Potential Biomarker of Human Nasopharyngeal Carcinoma and Its Growth is Inhibited by HDL-mimetic Nanoparticles

Abstract

Nasopharyngeal carcinoma (NPC) is a very regional malignant head and neck cancer that has attracted widespread attention for its unique etiology, epidemiology and therapeutic options. To achieve high cure rates in NPC patients, theranostic approaches are actively being pursued and improved efforts remain desirable in identifying novel biomarkers and establishing effective therapeutic approaches with low long-term toxicities. Here, we discovered that the scavenger receptor class B type I (SR-B1) was overexpressed in all investigated NPC cell lines and 75% of NPC biopsies, demonstrating that SR-B1 is a potential biomarker of NPC. Additional functional analysis showed that SR-B1 has great effect on cell motility while showing no significant impact on cell proliferation. As high-density lipoproteins (HDL) exhibit strong binding affinities to SR-B1 and HDL mimetic peptides are reportedly capable of inhibiting tumor growth, we further examined the SR-B1 targeting ability of a highly biocompatible HDL-mimicking peptide-phospholipid scaffold (HPPS) nanocarrier and investigated its therapeutic effect on NPC. Results show that NPC cells with higher SR-B1 expression have superior ability in taking up the core constituents of HPPS. Moreover, HPPS inhibited the motility and colony formation of 5-8F cells, and significantly suppressed the NPC cell growth in nude mice without inducing tumor cell necrosis or apoptosis. These results indicate that HPPS is not only a NPC-targeting nanocarrier but also an effective anti-NPC drug. Together, the identification of SR-B1 as a potential biomarker and the use of HPPS as an effective anti-NPC agent may shed new light on the diagnosis and therapeutics of NPC.

Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin

“…29 Normally the antitumor activity of sHDL is observed at relatively high dosages, such as 0.1-0.2 mg/mL of 22A-sHDL, is required to generate in vitro cytotoxicity in NCI-H295R and SW13 cells 35 and 250 mg/kg of R4F-sHDL to inhibit the tumor growth in vivo. 36 The improved activity of HCPT-sHDL is unlikely to be attributed to a synergetic effect between topoisomerase I inhibition by HCPT and cholesterol efflux by sHDL based on no statistically significant improvement in cytotoxicity of the physical mixture of sHDL and HCPT. However, the synergetic effect might be seen at other concentrations of sHDL and HCPT and it could not be ruled completely.…”

Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinoma

“…As the most important mediator in HDL-cholesterol metabolism, SR-B1 has been reported in several cancers. 10,11,13,15 Nevertheless, we knew little about the roles of SR-B1 in ccRCC. In our study, we explored the expression of SR-B1 in ccRCC tissues and found that SR-B1 expression was much higher in cancerous tissues compared with their normal counterparts.…”

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer

“…High SR-BI expression has been demonstrated in diverse cancer cell lines, including hepatoma, prostate, breast, colorectal, pancreatic, ovarian, and Baoying Yuan and Changshun Wu contributed equally to this work. nasopharyngeal cancer [15][16][17][18]. Danilo et al reported that SR-BI participates in breast cancer development and progression by mediating the selective HDL cholesteryl ester uptake and initiating PI3K/Akt signaling pathway [19].…”